Literature DB >> 16988256

Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3.

Vida A Dennis1, Ayanna Jefferson, Shree R Singh, Frédéric Ganapamo, Mario T Philipp.   

Abstract

It has been established that interleukin-10 (IL-10) inhibits inflammatory cytokines produced by macrophages in response to Borrelia burgdorferi or its lipoproteins. The mechanism by which IL-10 exerts this anti-inflammatory effect is still unknown. Recent findings indicate that suppressors of cytokine signaling (SOCS) proteins are induced by cytokines and Toll-like receptor (TLR)-mediated stimuli, and in turn they can down-regulate cytokine and TLR signaling in macrophages. Because it is known that SOCS are induced by IL-10 and that B. burgdorferi and its lipoproteins most likely interact via TLR2 or the heterodimers TLR2/1 and/or TLR2/6, we hypothesized that SOCS are induced by IL-10 and B. burgdorferi and its lipoproteins in macrophages and that SOCS may mediate the inhibition by IL-10 of concomitantly elicited cytokines. We report here that mouse J774 macrophages incubated with IL-10 and added B. burgdorferi spirochetes (freeze-thawed, live, or sonicated) or lipidated outer surface protein A (L-OspA) augmented their SOCS1/SOCS3 mRNA and protein expression, with SOCS3 being more abundant. Pam(3)Cys, a synthetic lipopeptide, also induced SOCS1/SOCS3 expression under these conditions, but unlipidated OspA was ineffective. Neither endogenous IL-10 nor the translation inhibitor cycloheximide blocked SOCS1/SOCS3 induction by B. burgdorferi and its lipoproteins, indicating that the expression of other genes is not required. This temporally correlated with the IL-10-mediated inhibition of the inflammatory cytokines IL-1beta, IL-6, IL-12p40, IL-18, and tumor necrosis factor alpha. Our data are evidence to suggest that expression of SOCS is part of the mechanism of IL-10-mediated inhibition of inflammatory cytokines elicited by B. burgdorferi and its lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988256      PMCID: PMC1594918          DOI: 10.1128/IAI.00678-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  66 in total

1.  SOCS-1 participates in negative regulation of LPS responses.

Authors:  Reiko Nakagawa; Tetsuji Naka; Hiroko Tsutsui; Minoru Fujimoto; Akihiro Kimura; Tatsuo Abe; Ekihiro Seki; Shintaro Sato; Osamu Takeuchi; Kiyoshi Takeda; Shizuo Akira; Koichi Yamanishi; Ichirou Kawase; Kenji Nakanishi; Tadamitsu Kishimoto
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  SOCS1/JAB is a negative regulator of LPS-induced macrophage activation.

Authors:  Ichiko Kinjyo; Toshikatsu Hanada; Kyoko Inagaki-Ohara; Hiroyuki Mori; Daisuke Aki; Masanobu Ohishi; Hiroki Yoshida; Masato Kubo; Akihiko Yoshimura
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

3.  Increased expression of the Th1-inducing cytokines interleukin-12 and interleukin-18 in cerebrospinal fluid but not in sera from patients with Lyme neuroborreliosis.

Authors:  M Grusell; M Widhe; C Ekerfelt
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

4.  Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages.

Authors:  Pooran Qasimi; Andrew Ming-Lum; Ali Ghanipour; Christopher J Ong; Michael E Cox; James Ihle; Nicolas Cacalano; Akihiko Yoshimura; Alice L-F Mui
Journal:  J Biol Chem       Date:  2005-12-12       Impact factor: 5.157

5.  Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses.

Authors:  Yaozhong Ding; Dongmei Chen; Adel Tarcsafalvi; Ruthie Su; Lihui Qin; Jonathan S Bromberg
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

6.  Differential acquired immune responsiveness to bacterial lipoproteins in Lyme disease-resistant and -susceptible mouse strains.

Authors:  Frédéric Ganapamo; Vida A Dennis; Mario T Philipp
Journal:  Eur J Immunol       Date:  2003-07       Impact factor: 5.532

Review 7.  TLR-induced negative regulatory circuits: role of suppressor of cytokine signaling (SOCS) proteins in innate immunity.

Authors:  Klaus Heeg; Alexander Dalpke
Journal:  Vaccine       Date:  2003-06-01       Impact factor: 3.641

8.  Triggering of Toll-like receptors modulates IFN-gamma signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling.

Authors:  Alexander H Dalpke; Susan Eckerle; Markus Frey; Klaus Heeg
Journal:  Eur J Immunol       Date:  2003-07       Impact factor: 5.532

9.  Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion.

Authors:  Rish K Pai; Marilyn Convery; Thomas A Hamilton; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

10.  Leishmania donovani-induced expression of suppressor of cytokine signaling 3 in human macrophages: a novel mechanism for intracellular parasite suppression of activation.

Authors:  Sylvie Bertholet; Harold L Dickensheets; Faruk Sheikh; Albert A Gam; Raymond P Donnelly; Richard T Kenney
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

View more
  19 in total

1.  SOCS1/3 expression levels in HSV-1-infected, cytokine-polarized and -unpolarized macrophages.

Authors:  Adam Craig Reichard; Nagarjuna Reddy Cheemarla; Nancy Jane Bigley
Journal:  J Interferon Cytokine Res       Date:  2014-06-23       Impact factor: 2.607

2.  Interleukin-10 alters effector functions of multiple genes induced by Borrelia burgdorferi in macrophages to regulate Lyme disease inflammation.

Authors:  Aarti Gautam; Saurabh Dixit; Mario T Philipp; Shree R Singh; Lisa A Morici; Deepak Kaushal; Vida A Dennis
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

Review 3.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

Review 4.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

5.  Localized production of IL-10 suppresses early inflammatory cell infiltration and subsequent development of IFN-γ-mediated Lyme arthritis.

Authors:  F Lynn Sonderegger; Ying Ma; Heather Maylor-Hagan; James Brewster; Xiaosong Huang; Gerald J Spangrude; James F Zachary; John H Weis; Janis J Weis
Journal:  J Immunol       Date:  2011-12-16       Impact factor: 5.422

6.  Adenoviral delivery of interleukin-10 fails to attenuate experimental Lyme disease.

Authors:  Charles R Brown; Annie Y-C Lai; Steven T Callen; Victoria A Blaho; Jennifer M Hughes; William J Mitchell
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

7.  Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3.

Authors:  Naimish R Patel; Katharine Swan; Xin Li; Souvenir D Tachado; Henry Koziel
Journal:  J Leukoc Biol       Date:  2009-04-21       Impact factor: 4.962

8.  Live Borrelia burgdorferi spirochetes elicit inflammatory mediators from human monocytes via the Toll-like receptor signaling pathway.

Authors:  Vida A Dennis; Saurabh Dixit; Shannon M O'Brien; Xavier Alvarez; Bapi Pahar; Mario T Philipp
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

Review 9.  SOCS1 and SOCS3 in the control of CNS immunity.

Authors:  Brandi J Baker; Lisa Nowoslawski Akhtar; Etty N Benveniste
Journal:  Trends Immunol       Date:  2009-07-28       Impact factor: 16.687

10.  CD14 signaling restrains chronic inflammation through induction of p38-MAPK/SOCS-dependent tolerance.

Authors:  Bikash Sahay; Rebeca L Patsey; Christian H Eggers; Juan C Salazar; Justin D Radolf; Timothy J Sellati
Journal:  PLoS Pathog       Date:  2009-12-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.